Fluad® influenza vaccine and risk to latex sensitive individuals
20 April 2018
There are two trivalent influenza vaccines available through the 2018 National Influenza Program for those aged 65 years and over: Fluad® (Seqirus) and Fluzone® (Sanofi PasteurTM).
The Therapeutic Goods Administration (TGA) have confirmed the presence of natural rubber latex in the needle sheath of the trivalent influenza vaccine Fluad® and have advised that anyone with a severe allergy to latex should not receive Fluad®.
In addition to this, as a precautionary measure, SA Health is advising that anyone with a known sensitivity or allergy to latex should not receive Fluad®.
There are no safety concerns regarding the Fluad® vaccine itself.
Fluzone® is latex free and can be used as alternative for those aged 65 years and over.
Immunisation providers are advised to:
- Assess the allergy status of all individuals prior to the administration of any vaccine.
- Do not use Fluad ® vaccine in individuals known to be sensitive or allergic to latex.
- Use Fluzone® in those aged 65 years and over who are known to be sensitive or allergic to latex.
- Confirm with patients they do not have a sensitivity or allergy to latex prior to the administration of Fluad®.
- As with all vaccinations, be prepared to treat immediate allergic reactions, including potential anaphylaxis.
Further information is available from the TGA safety alert: Fluad trivalent influenza vaccine (19 April 2018) available at Therapeutic Goods Administration: Current year alerts.
For all enquires please contact the Communicable Disease Control Branch, Immunisation Section on 1300 232 272.
For vaccination provider information see: Immunisation for health professionals
For recent public health alerts see: Health Alerts
For updated information on notifiable diseases in South Australia visit: Notifiable Disease Reporting